Month: June 2021

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

06/30/2021

Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Aleta is a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, and…

Read More

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

06/29/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ — Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body’s anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the…

Read More

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

06/28/2021

Excerpt from the Press Release: MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced preliminary results from its Phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel…

Read More

Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing

06/25/2021

Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell (OPC) transplant therapy for the treatment of spinal cord injury (SCI). Following feedback…

Read More

Onconova Therapeutics Announces The Peer-Reviewed Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Rigosertib Combined With Immune Checkpoint Blockade

06/25/2021

Excerpt from the Press Release: NEWTOWN, Pa., June 17, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of a preclinical study in the journal Molecular Cancer. The study, entitled “Novel induction of CD40 expression by tumor…

Read More

Patent Issued to IRISYS, LLC for a New Liposomal Anticancer Drug Delivery System

06/24/2021

Excerpt from the Press Release: SAN DIEGO, June 18, 2021 /PRNewswire/ –IRISYS, LLC, a San Diego-based provider of contract pharmaceutical development and manufacturing services, announced today that it has been issued U.S. Patent No. 11,033,530, Liposomal Anticancer Compositions. IRISYS scientists discovered a new way to deliver well-known anticancer therapeutics that may someday enable physicians to treat cancer patients…

Read More

Theravance Biopharma, Inc. Announces Top-line Results From Phase 2 Study Of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due To Covid-19

06/24/2021

Excerpt from the Press Release: DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo,…

Read More

Antibiotic Novobiocin found to kill tumor cells with DNA-repair glitch

06/24/2021

Excerpt from the Article: An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality. In…

Read More

CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

06/23/2021

Excerpt from the Press Release: STUDY SHOWS GUARDANT REVEAL™ BLOOD-ONLY LIQUID BIOPSY TEST PREDICTS RISK FOR COLORECTAL CANCER RECURRENCE WITH INDUSTRY-LEADING SENSITIVITY For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can…

Read More

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

06/23/2021

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, June 17, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first patient has been dosed in a Phase II basket trial of taletrectinib…

Read More